Mobile

An 8 week, double-blind, randomized, parallel group, active-controlled study to evaluate the efficacy and safety of the combination of Aliskiren /Amlodipine / HCTZ in patients with moderate to severe ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-003199-23

An 8 week, double-blind, randomized, parallel group, active-controlled study to evaluate the efficacy and safety of the combination of Aliskiren /Amlodipine / HCTZ in patients with moderate to severe hypertension

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the study is to demonstrate that a once daily dosing regimen of the triple combination of aliskiren/amlodipine/HCTZ is superior to the double combinations of aliskiren/amlodipine, aliskiren/HCTZ and amlodipine/HCTZ in lowering mean sitting systolic blood pressure (msSBP) in patients with moderate to severe hypertension.

Critère d'inclusion

  • Hypertension

Liens